Tom Powles: The 1st disitimab Vedotin and pembro in HER 1-3 urothelial carcinomas

Tom Powles shared a post on X:

“The 1st disitimab Vedotin (HER-2 MMAE ADC) and pembro showing 1st line response rates of 75% in HER 1-3+ UC (urothelial carcinomas). Toxicity profile looks distinct from EV (fatigue>skin). There is a global randomised phase 3 of DV and pembro and standard chemotherapy.”

Source: Tom Powles/X

Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.